Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
The Team
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
SubB2M CA15-3
SubB2M CA125
Exo-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
Analyst Reports
Heading &
Sub-heading can be edited through HQI
Investors
>
Analyst Reports
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
Analyst Reports
Filter by Year:
2024
2023
2022
27-Aug-2024
FY24: Solid Progress; Exosome Therapeutics Key Program to Watch
21-Aug-2024
NEURO-NET validated for Parkinson's Disease EV isolation
9-Aug-2024
Ready to Fund Key FY25 Priorities
5-Jun-2024
Engineered Exosomes Kill Breast Cancer Cells In-vitro
7-May-2024
Leveraging Exosome Advantage
28-Feb-2024
SubB2M/CA15-3 test: beats leading breast cancer test by 19%
1